(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522653-19-00

Acronym

ASK-PD0-CS002

Enrollment

Registered

2025-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease, Multiple System Atrophy

Brief summary

Incidence and severity of AEs (serious and non-serious)

Detailed description

For PD participants - Normalized PD motor diary times (Good ON, ON with troublesome dyskinesia, OFF), For PD participants - MDS-UPDRS part III (OFF and ON), For PD participants - MDS-UPDRS part II (OFF and ON), For PD participants - MDS-UPDRS part I, For PD participants - MDS-UPDRS part IV, For PD participants - Levodopa equivalent daily dose (LEDD), For PD participants - 18F-DOPA PET, For MSA participants - UMSARS parts I, II (ON), III, IV, For MSA participants - MSA-QoL

Interventions

DRUGCarbidopa

DRUGFluorodopa (18F)

DRUGAAV2-GDNF

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of AEs (serious and non-serious)	—

Secondary

Measure	Time frame
For PD participants - Normalized PD motor diary times (Good ON, ON with troublesome dyskinesia, OFF), For PD participants - MDS-UPDRS part III (OFF and ON), For PD participants - MDS-UPDRS part II (OFF and ON), For PD participants - MDS-UPDRS part I, For PD participants - MDS-UPDRS part IV, For PD participants - Levodopa equivalent daily dose (LEDD), For PD participants - 18F-DOPA PET, For MSA participants - UMSARS parts I, II (ON), III, IV, For MSA participants - MSA-QoL	—

Measure

Time frame

—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026